What is the appropriate treatment for a male patient with chronic balanitis and presumed non‑gonococcal urethritis presenting with an erythematous leathery glans, intermittent purulent discharge, dysuria, and recent resolved unilateral testicular pain, given negative chlamydia and gonorrhea tests?

Treatment Recommendation for Chronic Balanitis with Presumed Non-Gonococcal Urethritis

This patient requires immediate empiric treatment for persistent/recurrent non-gonococcal urethritis (NGU) with azithromycin 500 mg on day 1 followed by 250 mg daily for 4 days PLUS metronidazole 2 g single dose, while simultaneously obtaining expanded testing for Mycoplasma genitalium and Trichomonas vaginalis. 1

Clinical Reasoning

This presentation represents persistent urethritis (1.5–2 months duration) with objective findings (purulent discharge, dysuria, erythematous glans) despite negative initial chlamydia/gonorrhea testing. The "leathery" erythematous glans indicates chronic balanitis, while the intermittent purulent discharge and dysuria confirm ongoing urethritis. The resolved testicular pain suggests prior epididymitis, which commonly accompanies untreated urethritis 1.

Diagnostic Priorities Before Treatment

While treatment should begin immediately, obtain:

• NAAT testing for M. genitalium (most critical—this pathogen causes 10-30% of NGU and responds poorly to doxycycline) 2, 3
• NAAT for T. vaginalis (causes urethritis in men and requires specific treatment) 1, 4
• Repeat testing for N. gonorrhoeae and C. trachomatis (reinfection or false-negative initial test)
• Urinalysis with microscopy to document pyuria (≥10 WBC/hpf confirms urethritis) 4

Treatment Algorithm

First-Line Empiric Therapy (Given Negative Initial STI Testing)

For persistent NGU after presumed inadequate initial treatment:

• Azithromycin 500 mg PO on day 1, then 250 mg PO daily for 4 days 1, 3
  • This extended azithromycin regimen is superior to single-dose 1 g for M. genitalium and reduces resistance development
  • The 2024 EAU guidelines specifically recommend this regimen over single-dose azithromycin 1

PLUS

• Metronidazole 2 g PO single dose (or tinidazole 2 g single dose) 4
  • Covers T. vaginalis and anaerobes that may contribute to persistent symptoms
  • Essential given the chronic nature and purulent discharge

For the Chronic Balanitis Component

• Topical antifungal therapy should be discontinued (already failed OTC treatment)
• Keep glans dry and ensure balanced genital hygiene 5, 6
• Consider topical corticosteroid (hydrocortisone 1% BID for 7-14 days) if inflammatory balanitis persists after antimicrobial treatment 6

Critical Management Points

If Symptoms Persist After This Regimen

Moxifloxacin 400 mg PO daily for 7-14 days becomes the next step, particularly if M. genitalium is confirmed and macrolide resistance is suspected 1, 4, 2. The 2024 EAU guidelines explicitly recommend moxifloxacin for macrolide-resistant M. genitalium 1.

Partner Management

• All sexual partners within the preceding 60 days must be evaluated and treated empirically 4
• Partners should receive the same antimicrobial regimen
• Abstain from sexual intercourse until both patient and partners complete treatment and symptoms resolve 4

Test of Cure

• Mandatory if M. genitalium is detected: repeat NAAT ≥3 weeks after treatment initiation 2, 7
• Not routinely needed for chlamydia/gonorrhea if treated with recommended regimens and symptoms resolve 4
• Retest at 3-6 months regardless due to high reinfection rates 4

Common Pitfalls to Avoid

1. Do not retreat based on symptoms alone without objective evidence of urethritis (microscopy showing ≥10 WBC/hpf) 4. Persistent dysuria without pyuria may indicate chronic pelvic pain syndrome, not infection.

2. Avoid single-dose azithromycin 1 g as first-line therapy when M. genitalium is suspected—this drives macrolide resistance 3, 7. The 2016 European guideline explicitly moved away from this approach.

3. Do not assume treatment failure is due to non-compliance or reinfection without considering doxycycline-resistant U. urealyticum or M. genitalium 4.

4. The unilateral testicular pain history is significant—this suggests epididymitis from ascending urethral infection, reinforcing the need for aggressive treatment 1.

5. Screen for HIV and syphilis in any patient with confirmed STI 4.

Why This Approach

The 2024 EAU guidelines 1 represent the most current evidence and specifically address persistent NGU with extended azithromycin regimens. The combination with metronidazole covers the broader spectrum of pathogens causing persistent urethritis, including T. vaginalis (which causes 2-5% of male urethritis) 4, 2. The chronic balanitis is likely secondary to the ongoing urethritis and should improve with appropriate antimicrobial therapy, though topical management may be needed if inflammatory changes persist 6.

The key is treating empirically while awaiting M. genitalium results, as this pathogen is increasingly recognized as a major cause of persistent NGU and requires specific management to prevent treatment failure and resistance development 1, 3.